Next 10 |
home / stock / nktx / nktx articles
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing...
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeti...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 whil...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,3...
Over the past twenty days of trading, Nkarta Inc. (NASDAQ: NKTX), from February 23, 2024 to March 21, 2024 there is a potential Short Squeeze abou...
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adj...
Thursday, in its fourth quarter 2023 earnings release, Nkarta Inc (NASDAQ:NKTX) said it closed patient enrollment in its clinical trial o...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Nkarta, Inc. (NASDAQ: NKTX) posted a loss for the fourth quarter on Thursday. The company posted a quarterly loss of 57 cents per share, compared ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sp...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...